Regeneron Pharmaceuticals (NASDAQ:REGN) will release its quarterly earnings report on Friday, 2026-01-30. Here’s a brief overview for investors ahead of the announcement.
Analysts anticipate Regeneron Pharmaceuticals to report an earnings per share (EPS) of $9.69.
Investors in Regeneron Pharmaceuticals are eagerly awaiting the company’s announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It’s worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Past Earnings Performance
In the previous earnings release, the company beat EPS by $2.99, leading to a 0.24% drop in the share price the following trading session.
Here’s a look at Regeneron Pharmaceuticals’s past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 8.84 | 7.55 | 8.82 | 11.19 |
| EPS Actual | 11.83 | 12.89 | 8.22 | 12.07 |
| Price Change % | 0.00 | 2.00 | 5.00 | 3.00 |
Regeneron Pharmaceuticals Share Price Analysis
Shares of Regeneron Pharmaceuticals were trading at $751.13 as of January 27. Over the last 52-week period, shares are up 11.61%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analyst Observations about Regeneron Pharmaceuticals
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Regeneron Pharmaceuticals.
Analysts have provided Regeneron Pharmaceuticals with 13 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $812.31, suggesting a potential 5.32% upside.